Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (9680)	4/19/1999 11:37:00 AM
From: Edscharp	Read Replies (1) \| Respond to of 17367

From MTSL - April 8, 1999 "XOMA presented at the Sutro conference and will participate in the Carson Group's Future Leaders in the Biotech industry conference on April 15th as well. The company's next piece of news is going to be in relation to the meningococcemia trial. Good news will more than likely have a significant effect on the stock, as it will be the first time that Xoma has enjoyed success in a Phase III trial. Of course, there is always risk involved in investing in drug development, but we feel very confident that these results are going to be positive, and would not wait too much longer in adding to, or especially establishing positions. XOMA is a buy under $4."